Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix's Convertible Debt history runs 5 years deep, the most recent figure standing at $9.1 million for Q4 2023.

• On a quarterly basis, Convertible Debt fell 68.21% year-over-year to $9.1 million in Q4 2023; TTM through Dec 2023 was $9.1 million, a 68.21% decrease from a year earlier, with the FY2023 full-year figure at $9.1 million, down 68.21% from the prior year.
• Convertible Debt rose to $9.1 million in Q4 2023 per OCUL's latest filing, from $8.8 million in the prior quarter.
• Across five years, Convertible Debt topped out at $30.0 million in Q2 2023 and bottomed at $8.8 million in Q3 2023.
• The 5-year median for Convertible Debt is $25.3 million (2020), against an average of $24.3 million.
• Across the five-year window, Convertible Debt grew 10.27% in 2020 and tumbled 68.87% in 2023, its largest moves.
• Year by year, Convertible Debt stood at $24.3 million in 2019, then climbed by 0.01% to $24.3 million in 2020, then gained by 8.75% to $26.4 million in 2021, then advanced by 8.75% to $28.7 million in 2022, then slumped by 68.21% to $9.1 million in 2023.
• Per Business Quant, the three latest OCUL Convertible Debt figures stand at $9.1 million (Q4 2023), $8.8 million (Q3 2023), and $30.0 million (Q2 2023).